News

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...
The Department of Health and Human Services will cancel contracts and pull funding for some vaccines that are being developed ...
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
Moderna announced that in the Phase 1/2 study, mRNA-1083 appeared to achieve antibody titers similar to or greater than both the licensed flu shot and the updated Covid-19 vaccine. The ...
Moderna’s second-quarter sales fell less sharply than Wall Street expected as it works to expand its offerings amid weakening ...
The European Union's drug regulator has recommended approval of Moderna's updated formulation of COVID-19 shot Spikevax, the ...
The U.S. health department is canceling or scaling back 22 BARDA-backed mRNA projects worth nearly $500 million, shifting ...
The researchers followed participants from October 2024 to January 2025. Median age was 76 years, and 54.2% were women. By ...